

## Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares

Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Morten Albrechtsen (CEO), Andreas Kjær (CSO), Henrik Moltke (CFO), Mats Thoren (board member) and Micaela Sjøkvist (board member) have purchased shares. Shomit Ghose (board member) has sold shares to pay income tax on his shareholdings in FluoGuide due to U.S. tax regulations.

FluoGuide A/S				
Overview of share transactions September 14, 2021, of members of the Board and Management				
	Number of shares	Average Share price***)	Shareholding after purchase	Votes and capital %
<b>Member of Board and Management that has bought shares</b>				
Micaela Sjøkvist, Board member	741	109.71	62,163	0.55%
Mats Thorén, Board member	741	109.71	741	0.01%
Henrik Moltke, CFO	1,216	109.71	1,216	0.01%
Life Science IVS*)	1,216	109.71	2,126,107	18.78%
Wexotec ApS **)	1,216	109.71	1,488,610	13.15%
<b>Member of Board that has sold shares</b>				
	Number of shares	Average Share price***)	Shareholding after sale	Votes and capital %
Shomit Ghose	4,167	104.82	35,643	0.31%

\*) Owned by Andreas Kjær, CSO, Board member

\*\*) Owned by Morten Albrechtsen, CEO

\*\*\*) Trade between 30 August and 13 September 2021

“Due to the success of FluoGuide, I have to pay tax on my shareholdings of FluoGuide and I have decided to finance this by selling some of my shares in FluoGuide”, says Shomit Ghose, member of the Board of Directors of FluoGuide and continues: “I have a strong confidence in FluoGuide with a visionary leadership, promising technology and execution power I have rarely seen even compared to a U.S. standard. I am very proud to be part of its exciting development and committed to contribute to fully utilizing FluoGuide’s data utilization potential in advance surgical guidance.”

The transactions are reported to The Danish Financial Supervisory Authority (Danish: “Finanstilsynet”) in accordance with current regulations.

This disclosure contains information that FluoGuide is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-09-2021 11:55 CET.

Morten Albrechtsen, CEO  
 FluoGuide A/S  
 Phone: +45 24 25 62 66  
 Email: ma@fluoguide.com

Certified Adviser:  
Svensk Kapitalmarknadsgransking AB  
Phone: +46 70 755 95 51  
Email: ca@skmg.se

### **About FluoGuide**

FluoGuide's primary focus is to maximize surgical outcomes in oncology. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient's chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker "FLUO".